Capricor Therapeutics, Inc. $CAPR Stock Position Decreased by Rafferty Asset Management LLC

Key Points

• Rafferty Asset Management LLC reduced its stake in Capricor Therapeutics by 34.3%, now owning approximately 0.18% of the company valued at $788,000.
• Capricor Therapeutics' stock has fluctuated significantly, with a one-year range between $3.98 and $23.40, currently trading at $6.28.
• Analysts have mixed ratings on Capricor's stock, with target prices ranging from $12.00 to $43.00, indicating a generally positive outlook despite recent earnings misses.

Rafferty Asset Management LLC cut its stake in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 34.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,988 shares of the biotechnology company's stock after selling 43,323 shares during the period. Rafferty Asset Management LLC owned 0.18% of Capricor Therapeutics worth $788,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of CAPR. Citizens Financial Group Inc. RI acquired a new stake in Capricor Therapeutics during the first quarter valued at $95,000. Arizona State Retirement System acquired a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $111,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Capricor Therapeutics by 31.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,246 shares of the biotechnology company's stock worth $126,000 after purchasing an additional 3,162 shares during the period. ProShare Advisors LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at $142,000. Finally, Voya Investment Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at $150,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on CAPR. Piper Sandler restated an "overweight" rating and issued a $20.00 price target on shares of Capricor Therapeutics in a research report on Friday, July 11th. Cantor Fitzgerald reiterated an "overweight" rating and set a $30.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 14th. Roth Capital dropped their price objective on Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a research report on Monday, July 14th. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Finally, Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, Capricor Therapeutics has a consensus rating of "Buy" and a consensus price target of $22.56.

Capricor Therapeutics Stock Performance

Shares of NASDAQ CAPR traded down $0.05 during trading on Wednesday, reaching $6.28. The stock had a trading volume of 839,694 shares, compared to its average volume of 1,336,131. Capricor Therapeutics, Inc. has a one year low of $3.98 and a one year high of $23.40. The stock has a market cap of $287.12 million, a PE ratio of -3.83 and a beta of 0.73. The firm's 50 day moving average price is $7.92 and its two-hundred day moving average price is $10.27.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative net margin of 181.71% and a negative return on equity of 62.71%. On average, research analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.